by TractManager | Sep 1, 2021 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Axonics Sacral Neuromodulation (Axonics Modulation Technologies Inc.) for the management of urinary dysfunction.If...
by TractManager | Sep 1, 2021 | Precision Medicine Insights
This report reviews clinical study abstracts and clinical practice guidelines addressing molecular testing for monoclonal T-cell receptor (TCR) gene rearrangements to aid diagnosis and/or staging of mature/peripheral T-cell lymphoma.If you have a Hayes login, click...
by TractManager | Sep 1, 2021 | News
The Food and Drug Administration (FDA) is requiring new and updated warnings for Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib; Pfizer), Olumiant (baricitinib; Eli Lilly and Co.), and Rinvoq (upadacitinib; AbbVie Inc).The FDA completed a review of a...
Recent Comments